You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Night Alert Prompting System

    SBC: AMRON CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term aim of this program of research is to develop a Night Alert Prompting System (NAPS) that can be used by caregivers of home-dwelling cognitively impaired (CI) individuals to prevent nighttime injuries and unattended exits, improve caregiver sleep, reduce caregiver worry, and thereby delay institutionalization of the CI individuals. The primary func ...

    STTR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health
  2. ANTI-ANDROGENIC MECHANISM OF A NEW COMPOUND

    SBC: ANDROSCIENCE CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Androgen blockage therapy may relieve the symptom of an advanced, localized prostate tumor; however, once the tumor evolves into a hormone-refractory stage, there is no effective treatment. A continuous activation of AR by antiandrogens (used in androgen blockage therapy) or other "nonconventional" agonists may contribute to prostate cancer progression in patie ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  3. Heterologous Production of Eleutherobin Precursors

    SBC: AMYRIS BIOTECHNOLOGIES            Topic: N/A

    DESCRIPTION (provided by applicant): Terpenoids are a diverse class of natural compounds with equally diverse and potent bioactivities. Because the practical use of terpenoids hinges on the ability to extract or synthesize these compounds, only the most abundant or easily synthesized compounds have been commercially developed. The long-term goal of this Small Business Technology Transfer Phase I p ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  4. Histone Deacetylase Inhibitors for Cancer Treatment

    SBC: Angiogen, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Histone deacetylases (HDACs) comprise a family of enzymes that catalyze the removal of acetyl groups from lysine residues of histones. They mediate chromatin remodeling and gene expression. HDAC inhibitors are potent inducers of growth arrest, differentiation or apoptic cell death and suppress cell proliferation in a variety of transformed cells in culture and ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Nano-Ceramic for Metabolic Stem Cell Engineering

    SBC: Angstrom Medica, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall objective of this project is to develop a clinically and commercially viable tissue engineered bone construct using nanocrystalline ceramic scaffolds for proliferating and differentiating adipose-derived progenitor cells into cells of the osteogenic lineage. The use of a nanostructured hydroxyapatite (nano-HAP) scaffold offers several advantages for ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Nanostructured Calcium Phosphate for Gene Delivery to Bone

    SBC: Angstrom Medica, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoporosis is a major and growing health care problem that responds inadequately to standard pharmacologic therapy. Because of its low bone mineral density, osteoporotic bone is mechanically weak and fractures more easily than normal bone. Moreover, fracture repair is compromised in osteoporotic patients. The work described in this Phase I STTR proposal aims ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Peptide Transduction-based Therapies for CF

    SBC: Ansata Therapeutics, Inc.            Topic: N/A

    DESCRIPTION: (provided by applicant): Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding CFTR that results in a significantly shorter lifespan as well as associated pathologies. Unfortunately, none of the currently available treatments are able to halt the progression of the disease. The predominant CFTR mutation, deltaF508, results in a mutant protein that is retai ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  8. COSMOBOING! THERAPEUTIC EXERCISE SYSTEM

    SBC: Anthrotronix, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term goal of the CosmoBoing! Therapeutic Exercise System is to develop a child-friendly, engaging tool for assuring that children with disabilities participate in and benefit from prescribed therapeutic exercise. The system will serve two populations of children. The first group is comprised of children with acquired and developmental disabilities who ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  9. A P. falciparum MSP1 p42/QS-21 malaria vaccine

    SBC: Agenus Inc.            Topic: N/A

    DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a disease which affects more than 300 million people each year and is fatal for 1.5 million. The overall objective of this STTR Phase I project is to produce a cGMP malaria vaccine consisting of the 42 kDa C-terminal polypeptide of P. falciparum merozoite surface protein-1 (MSP1.42) to be formulated with ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  10. New APEX diagnostic for hereditary sensorineural hearing loss

    SBC: APEX DX, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): In developed countries, approximately 1:1000 children are born deaf and approximately 1:300 children are born with some lesser degree of hearing loss. At least 50% of the deafness and hearing impairment is likely to be attributable to genetic factors, with a large number of genes involved in the pathogenesis. The molecular genetic basis for the majority of case ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government